eRibo Pro™ is an exclusively licensed method for profiling ribosome-associated RNAs and the transcriptome. The eRibo Pro ribosome profiling service is an end-to-end solution that streamlines the ribosome profiling process, from sample processing to sequencing and data analysis.
Widespread application of RNA-Seq has provided substantial insight into the role of gene expression. However it fails to capture regulation at the level of translation. Furthermore, while many people utilize RNA-Seq data to estimate the cellular proteome characterization of ribosome-associated RNAs serves as a closer proxy to estimate a sample’s protein levels.
This comprehensive service includes mapping of ribosome protected fragments (RPFs) and identification of differentially transcribed and translated genes with interactive reports that allow researchers to make data driven insights. The ability to quantify ribosome occupancy transcriptome-wide using eRibo Pro will enable translatome studies to be applied more broadly in the context of research and in the development of therapeutics.
Eclipsebio is sole licensee of the Ribo-seq method covered by U.S. Patent Numbers 8,486,865, 9,284,547 and 9,677,068.
Publications Citing eRibo Pro™
2023 | eRibo
Genome-Wide Analysis in Vivo of Translation with Nucleotide Resolution Using Ribosome Profiling
2023 | eRibo
The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments
eRibo Pro Data Sheet